<DOC>
	<DOCNO>NCT01214759</DOCNO>
	<brief_summary>This study evaluate safety tolerability combination truvada raltegravir give 28 day prevention HIV infection .</brief_summary>
	<brief_title>Truvada Plus Raltegravir Nonoccupational Post-exposure Prophylaxis ( nPEP )</brief_title>
	<detailed_description>Non-Occupational Post-Exposure Prophylaxis ( nPEP ) sexual exposure HIV recommend Centers Disease Control ( CDC ) . Although efficacy data exist Post-Exposure Prophylaxis ( PEP ) sexual exposure , PEP show reduce HIV transmission exposure situation occupational exposure mother-to-child transmission . The role nPEP new agent approve treatment HIV infection remain unknown . The anti-HIV drug raltegravir work early life cycle virus , integrate human DNA . It side effect drug interaction make ideal drug nPEP regimen . We aim ass safety tolerability combination truvada raltegravir nPEP .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients must least 18 year age HIV uninfected basis negative HIV rapid test , EIA Western blot , without sign symptom acute HIV infection Able understand provide consent HighRisk Exposure Characteristic ( One , unprotected failed condom use ) : Receptive Anal Intercourse Insertive Anal Intercourse Receptive Vaginal Intercourse Insertive Vaginal Intercourse Receptive Oral Intercourse Intraoral Ejaculation know HIV+ source HighRisk Source ( One ) : Known HIV positive MSM MSM/W CSW Sexual perpetrator Partner one Exposure within 72 hour presentation Not know HIV1 positive No countermanding concomitant medication allergies Patients &lt; 18 year age Unable understand provide consent Nonoccupational exposure HIV1 recent enough commence first dose study medication within 72 hour exposure Known HIV positive Any condition opinion intake provider seriously compromise patient 's ability comply protocol , include adherence nPEP medication Demonstrated HIV1 positive rapid test Unwillingness commit barriermethod ( male and/or female condom ) use HIV negative status confirm 6 month exposure Unwillingness breastfeed woman transition formula feed Any active psychiatric illness active drug alcohol abuse , opinion investigator , could prevent compliance study procedure Pregnancy Chronic hepatitis B infection , diagnose either positive serum HBsAg positive serum HBV DNA ; prior lamivudine therapy hepatitis B Creatinine clearance le 30 mL/min calculate CockcroftGault formula Unwillingness participate study procedure , include Mental Health referral intervention Known intolerance allergy tenofovir DF , emtricitabine raltegravir Use prohibit concomitant medication : dilantin , phenobarbital rifampin use raltegravir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>prevention</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Truvada</keyword>
</DOC>